UK-headquartered, Nasdaq-listed Silence Therapeutics, a clinical-stage biotech company developing short interfering RNA (siRNA) therapies, is raising approximately US$150m through the issue of an underwritten ADS offering. Underwriters have 30-day option…
UK: Silence Therapeutics announces proposed public offering of US$150m of ADS
…
…






